Loading...
•
Jun 30, 2024
Heron Therapeutics Q2 2024 Earnings Report
Reported financial results for Q2 2024 and narrowed financial guidance.
Key Takeaways
Heron Therapeutics reported a net product sales increase in the second quarter of 2024, driven by growth in both acute care and oncology care franchises. The company is also improving financial efficiency by growing revenues, improving margins, and reducing expenses.
Second quarter Net Product Sales were $36.0 million, an increase from $31.8 million for the same period in 2023.
ZYNRELEF VAN PDUFA goal date set for September 23, 2024.
ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief (NOPAIN Act).
Adjusted operating expenses guidance for 2024 is being narrowed from $108.0 million to $116.0 million to a revised $107.0 million to $111.0 million.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
The Company narrows its full-year 2024 guidance for Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net: $138.0 to $158.0 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income